Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025